Rink-Sept-2025-350

We will be holding the next meeting IN PERSON Research Incubator in Neonatal Kidney Disease (RINK) on September 26th, 2025 from 10am-4pm EST.

The RINK is a multidisciplinary research consortium that will build on the success of the Neonatal Kidney Collaborative and foster continue collaboration to improve outcomes in neonates with kidney disease. We anticipate that the RINK will serve to expand the NKC's research portfolio to include more investigator drive studies from a broader range of investigators and provide flexibility to NKC members to participate in studies ranging in sizes and scope from small investigator driven studies to clinical trials.

The meeting will be on Friday September 26th, 2025 to coincide with the 5th International Symposium on Acute Kidney Injury in Children in Cincinnati, OH. We are still finalizing the exact timing, but will likely run morning to afternoon (10am-4pm, to be finalized).  Please plan your travel accordingly. Please consider attending the meeting Cincinnati AKI meeting sign-up . This is a great meeting for trainees to present their work as well.

The event is FREE to participate for those registered for the AKI meeting. Must Register for the RINK meeting Below.

Register Today!

UPCOMING


RINK September 2025
Cincinnati, Ohio, USA
Hilton Cincinnati Netherland Plaza
September 26th, 2025 from 10am-4pm EST

ARCHIVES

RINK DETAILS AND FAQ

 

What is the RINK?

Develop a multidisciplinary research consortium that will aim to build on the success of the Neonatal Kidney Collaborative and foster continued collaboration to improve outcomes in neonates with kidney disease.   The RINK would be constructed based on the model of the PNRC (Pediatric Nephrology Research Consortium Home (pnrconsortium.org )). In the PNRC, pediatric nephrologists meet periodically (twice per year) to brainstorm research ideas, present future studies, and review progress of on-going studies.  The RINK will seek to emulate this model.

How does it work?

Based on this model, any active member in good standing is eligible to bring study concepts forward and to provide an opportunity for improvement, vetting, approval, and ultimately assist with study execution.  Once a study is approved, the study team will present the study to the consortium and will solicit center participation. Each individual at a participating center that contributes at least one patient will receive authorship. This framework provides the flexibility for the consortium to perform studies ranging in size and scope from small investigator driven studies to clinical trials. This model will provide a framework, structure, and source of preliminary data for larger, funded studies and clinical trials.  The PNRC now serves as an important component in the clinical trial framework within Pediatric Nephrology. This model does not provide statistical support for studies, and the principal investigators are expected to have this support to complete their studies. The RINK will serve to expand the NKC's research portfolio to in include more investigator driven studies from a broader range of investigators.

What are the goals of the RINK?

We will provide the infrastructure to unite neonatologists, pediatric nephrologists, basic scientists, psychologists, patient families, adult nephrologists, and maternal fetal medicine physicians to address unmet research needs. We hope to encourage participation from nurse practitioners, pharmacists, and dieticians. Our goal is a diverse network of participants to develop and execute important research initiatives.  We anticipate that as the RINK is successful, industry sponsors will look towards to RINK for research related to neonatal nephrology.

How will the RINK meet?

As we initiate the infrastructure of the RINK, we will hold virtual meetings to reduce cost. Once at full capacity, our goal will be three meetings per year with 1-2 in-person meeting per year (perhaps in conjunction with other meetings - such as pAKI, PAS (in the spring) or INNS as a pre or post meeting). We anticipate one day dedicated to facilitating collaboration and developing research ideas.  See Table 1 for a proposed schedule of meetings.

How is the RINK organized?

We plan to develop several "working groups" to allow attendees to gravitate to groups with shared interests.  During the first portion of the meeting, there would be a time where working groups can brainstorm ideas. We anticipate the first few meetings will be solely brain storming session. Once at full capacity, the brainstorming session will be followed by presentations of new studies that are seeking participants.  Each meeting would conclude with presentations of completed work. The headers below describe the proposed workings of the RINK.

What are examples of potential working groups?

The purpose of the working groups is to serve as an opportunity for members to sit in a room together (in-person or virtually) to brainstorm research ideas and priorities. NKC members will be surveyed to identify priorities for working groups.  While there will remain a large neonatal critical care nephrology focus, the working groups will seek to encompass the breadth of neonatal nephrology. Furthermore, new working groups can be suggested by members as interests/topics change.

Examples of potential working groups:
  • Fetal programming/ Fetal origins of CKD
  • Biomarkers/ risk stratification/ Early diagnostics
  • Epidemiology/ Observational Studies
  • Devices/ trials/ etc.
  • KST: CRRT, PD, ECMO
  • CAKUT/Genetic kidney diseases

RINK STUDIES

The below studies in the RINK are actively seeking sites. These studies are listed below with contact information for the study PI:

Study Name
 
Congenital anomalies of the kidney and urinary tract (CAKUT) and Hepatoblastoma (HB)  
Contact
 
Meredith Schuh, Cincinnati Children's Hospital, meredith.schuh@cchmc.org
Overview
 
This is a multi-center retrospective case series evaluating the characteristics of patients with CAKUT and HB to understand the general incidence and develop screening protocols. Additionally, evaluating survival of patients with CAKUT and HB compared to HB without CAKUT may support the future enrollment of these patients to clinical trials.
Aims
 
Aim 1: To characterize children with CAKUT who develop liver tumors (HB and HCC) and identify the general incidence of HB in patients with CAKUT
Aim 2:  To evaluate the outcomes of patients with HB and CAKUT compared to patients with HB without CAKUT
Study Name
 
Neurodevelopmental outcomes in infants with end stage kidney disease
Contact
 
Melissa Zhou, Stanford, zhoums@stanford.edu
Overview
 
Through a multi-center retrospective cohort study, we aim to evaluate the spectrum of neurodevelopmental outcomes in a contemporary cohort of infants with end stage kidney disease (dialysis need within the first 6 months life, born 2018-2023).
Aims
 
We plan to summarize the developmental assessment data available for this cohort at 12-16 months corrected age, describe neurologic complications, and explore current utilization practices of various special support services (i.e. developmental peds, PT/OT, SLP, early intervention).
Study Name
 
Outcomes of congenital kidney failure after amnioinfusion
Contact
 
Shina Menon, Stanford, shinam@stanford.edu
Overview
 
Congenital kidney failure is often secondary to various congenital anomalies of the kidneys and urinary system (CAKUT). In its most severe form, it may be diagnosed in utero when it presents with fetal anuria and anhydramnios by the second trimester, which subsequently impairs pulmonary development and may cause pulmonary hypoplasia.
Aims
 
Aim 1: Evaluate pulmonary function (as measured by amount of respiratory support) at various timepoints in infants with CKF whose mothers received amnioinfusions.
Aim 2: Evaluate prenatal, perinatal, and postnatal factors that distinguish survival at the various timepoints.
Aim 3: Describe other morbidities at hospital discharge and 1 year in infants with CKF whose mothers received amnioinfusions.
Study Name
 
AWAKEN 2.0: Towards Expanding Our Understanding of Neonatal Acute Kidney Injury
Contact
 
Michelle Starr, Indiana Univeristy, mcstarr@iu.edu
Overview
 
AWAKEN 2.0 is a multi-center multi-national retrospective analysis. Using a similar methodology to the original AWAKEN study, we will screen all infants admitted to NICUs to enable us to answer specific hypothesis regarding the following 3 inter-connected specific aims:
Aims
 
AIM 1. Describe prevalence of AKI in a multi-national multi-center retrospective cohort, 5 years after the original AWAKEN study.
AIM 2. Determine if AKI can predict mortality, length of stay, and discharge serum creatinine.
AIM 3. Determine if AKI can predict chronic kidney disease, recurrent AKI and hypertension during early childhood.

RINK RULES OF ENGAGEMENT

RINK Rules of Engagement

  1. Each study proposal will require a neonatologist and pediatric nephrologist for submission.
  2. Each proposal will require a co-PI from at least two institutions.
  3. Each center that submits data will be a named author on the study. For larger multicenter work this may come in the form of a collaborator mechanism but can be discussed on a case by case basis.
  4. Each study PI is responsible for funding, biostats, etc. The RINK arm of the RC simply provides the framework/infrastructure to build and cultivate the research.
  5. At meetings, study PI's will be expected to provide updates of new studies, work in progress, actively enrolling studies, and studies that have completed enrollment.
  6. While the RINK is the name of the group, studies that are performed by the RINK mechanism will need to include the following in the title, "a Neonatal Kidney Collaborative study." This will allow for the NKC to be Pubmed citable.  If this study is done in conjunction with other multicenter collaborative this can be discussed between the RINK leadership and the study PI.
  7. The RINK will actively seek to ensure that study and collaboration opportunities are extended to include NKC sites outside of the United States. Meetings that are virtual in nature will be held at times to optimize the ability for non-North American sites to participate. Furthermore, specific updates and follow-up to in-person meetings will actively solicit and encourage participation from sites outside of North America.
  8. Each protocol will be reviewed by the NKC's Protocol sub-committee prior to soliciting participants.
  9. All abstracts and publications will be reviewed by the NKC's Publications sub-committee prior to submission.
  10. Order of authorship will be determined by the principal investigators of each study. Each individual at a participating center that contributes at least one patient will receive by-line authorship. In circumstances where there are multiple large multicenter consortia collaborative mechanisms for authorship can be discussed. The authorship plan will be included as part of the proposal submission.
  11. Each center will identify a site lead for the RINK that will serve as the liaison.  This position will initially serve to answer site questions surrounding site characteristics when applicable for studies (number of patients treated with a condition, etc.) This position is a leadership that participants can place onto their CV.  This person will become more important for the development and execution of longitudinal studies, clinical feasibility, etc.

Protocol/ Study development would evolve as follows Figure 1:

  1. Developing ideas at Meeting 1 with topic based individual working groups. With the initial meetings, we will develop the working groups.  Participants will self-identify to a working group based on their interest and are freely allowed to move between working groups at different meetings. The working groups will identify study PI's at the meetings.
  2. In between meetings, teams will assist the PI in protocol development, ideally have it reviewed and approved by the NKC RC's Protocol sub-committee. If further input is needed this can be presented for feedback at a subsequent RINK meeting.
  3. Once approved, the approved protocol will be distributed to all NKC sites to identify interested parties and to solicit sites to participate.
  4. Ideally, a study is finalized and kicks off after meeting 2. Investigators will be encouraged to work efficiently with proposals, but timelines will remain flexible.
rink-figure-1
 
rink-figure-2